Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05469048 · ClinicalTrials.gov registry record
Near Patient Molecular Testing in Sepsis
A clinical trial, sponsored by Immunexpress.
- Completed
- Registry status
- 63
- Enrollment target
NCT05469048: Completed study, sponsored by Immunexpress.
NCT05469048 is a clinical trial that has completed, run by Immunexpress. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05469048 has completed, sponsored by Immunexpress.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.
Primary Outcome
Percentage of correctly identified patients with sepsis or non-infectious systemic inflammation using SeptiCyte RAPID compared to clinical assessments using routine clinical, laboratory, and other findings.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-03-12 |
| Est. Completion | 2022-10-31 |
What the finished NCT05469048 record still lists
NCT05469048 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05469048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05469048 about?
NCT05469048 is a clinical study titled "Near Patient Molecular Testing in Sepsis". The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.
What is the current status of trial NCT05469048?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2020-03-12. Estimated completion is 2022-10-31.
Who is sponsoring clinical trial NCT05469048?
This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI